News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
775,007 Results
Type
Article (58703)
Company Profile (613)
Press Release (715690)
Multimedia
Podcasts (106)
Webinars (16)
Section
Business (218826)
Career Advice (2840)
Deals (37957)
Drug Delivery (121)
Drug Development (86708)
Employer Resources (183)
FDA (17794)
Job Trends (16301)
News (373244)
Policy (37435)
Tag
Academia (2929)
Academic (1)
Accelerated approval (11)
Adcomms (28)
Allergies (103)
Alliances (54137)
ALS (118)
Alzheimer's disease (1548)
Antibody-drug conjugate (ADC) (179)
Approvals (17763)
Artificial intelligence (374)
Autoimmune disease (34)
Automation (19)
Bankruptcy (390)
Best Places to Work (12426)
BIOSECURE Act (22)
Biosimilars (136)
Biotechnology (423)
Bladder cancer (100)
Brain cancer (40)
Breast cancer (385)
Cancer (3035)
Cardiovascular disease (241)
Career advice (2391)
Career pathing (34)
CAR-T (202)
CDC (40)
Cell therapy (545)
Cervical cancer (24)
Clinical research (71024)
Collaboration (1095)
Company closure (3)
Compensation (713)
Complete response letters (34)
COVID-19 (2889)
CRISPR (65)
C-suite (350)
Cystic fibrosis (118)
Data (3070)
Decentralized trials (2)
Denatured (32)
Depression (72)
Diabetes (370)
Diagnostics (6872)
Digital health (26)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (162)
Drug pricing (149)
Drug shortages (35)
Duchenne muscular dystrophy (133)
Earnings (91695)
Editorial (47)
Employer branding (21)
Employer resources (159)
Events (122217)
Executive appointments (894)
FDA (19536)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (1000)
Gene editing (143)
Generative AI (33)
Gene therapy (419)
GLP-1 (897)
Government (5076)
Grass and pollen (5)
Guidances (181)
Healthcare (20402)
HIV (43)
Huntington's disease (32)
IgA nephropathy (44)
Immunology and inflammation (170)
Immuno-oncology (10)
Indications (40)
Infectious disease (3083)
Inflammatory bowel disease (163)
Inflation Reduction Act (11)
Influenza (69)
Intellectual property (125)
Interviews (502)
IPO (17420)
IRA (53)
Job creations (4331)
Job search strategy (1998)
Kidney cancer (14)
Labor market (52)
Layoffs (564)
Leadership (26)
Legal (9330)
Liver cancer (85)
Longevity (12)
Lung cancer (422)
Lymphoma (213)
Machine learning (11)
Management (63)
Manufacturing (432)
MASH (95)
Medical device (14450)
Medtech (14455)
Mergers & acquisitions (21265)
Metabolic disorders (935)
Multiple sclerosis (101)
NASH (18)
Neurodegenerative disease (132)
Neuropsychiatric disorders (39)
Neuroscience (2285)
NextGen: Class of 2025 (7358)
Non-profit (4970)
Now hiring (47)
Obesity (476)
Opinion (276)
Ovarian cancer (104)
Pain (121)
Pancreatic cancer (122)
Parkinson's disease (197)
Partnered (22)
Patents (317)
Patient recruitment (173)
Peanut (54)
People (61758)
Pharmaceutical (127)
Pharmacy benefit managers (25)
Phase I (22023)
Phase II (31043)
Phase III (23334)
Pipeline (1688)
Policy (233)
Postmarket research (3035)
Preclinical (9545)
Press Release (71)
Prostate cancer (148)
Psychedelics (42)
Radiopharmaceuticals (274)
Rare diseases (514)
Real estate (6647)
Recruiting (71)
Regulatory (25738)
Reports (52)
Research institute (2606)
Resumes & cover letters (464)
Rett syndrome (10)
RNA editing (9)
RSV (58)
Schizophrenia (96)
Series A (166)
Series B (118)
Service/supplier (25)
Sickle cell disease (66)
Special edition (22)
Spinal muscular atrophy (162)
Sponsored (35)
Startups (3988)
State (2)
Stomach cancer (17)
Supply chain (81)
Tariffs (64)
The Weekly (72)
Vaccines (901)
Venture capital (57)
Weight loss (311)
Women's health (47)
Worklife (19)
Date
Today (91)
Last 7 days (393)
Last 30 days (1978)
Last 365 days (33187)
2025 (18017)
2024 (37460)
2023 (42038)
2022 (53393)
2021 (58163)
2020 (57041)
2019 (50262)
2018 (38242)
2017 (35326)
2016 (35344)
2015 (41223)
2014 (35184)
2013 (30569)
2012 (32685)
2011 (33291)
2010 (31424)
Location
Africa (979)
Alabama (67)
Alaska (7)
Arizona (264)
Arkansas (14)
Asia (44966)
Australia (7508)
California (7735)
Canada (2400)
China (717)
Colorado (335)
Connecticut (343)
Delaware (203)
Europe (99319)
Florida (1152)
Georgia (261)
Hawaii (2)
Idaho (62)
Illinois (699)
India (30)
Indiana (381)
Iowa (18)
Japan (237)
Kansas (114)
Kentucky (32)
Louisiana (17)
Maine (64)
Maryland (1098)
Massachusetts (5882)
Michigan (257)
Minnesota (474)
Mississippi (3)
Missouri (99)
Montana (32)
Nebraska (25)
Nevada (83)
New Hampshire (71)
New Jersey (2162)
New Mexico (31)
New York (2166)
North Carolina (1196)
North Dakota (10)
Northern California (3340)
Ohio (246)
Oklahoma (17)
Oregon (45)
Pennsylvania (1654)
Puerto Rico (17)
Rhode Island (39)
South America (1366)
South Carolina (36)
South Dakota (1)
Southern California (2869)
Tennessee (128)
Texas (1182)
United States (28996)
Utah (226)
Virginia (208)
Washington D.C. (79)
Washington State (674)
West Virginia (4)
Wisconsin (84)
775,007 Results for "idorsia pharmaceuticals us inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
June 23, 2025
·
4 min read
Press Releases
Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia
June 10, 2025
·
6 min read
Press Releases
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
May 21, 2025
·
18 min read
Press Releases
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
June 25, 2025
·
6 min read
Press Releases
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
May 2, 2025
·
4 min read
Press Releases
Idorsia publishes its Annual Report 2024
March 27, 2025
·
12 min read
Press Releases
Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset
April 30, 2025
·
26 min read
Press Releases
Idorsia announces financial results for 2024
March 4, 2025
·
25 min read
Press Releases
Idorsia and Viatris update their collaboration for selatogrel and cenerimod
February 26, 2025
·
4 min read
Press Releases
Idorsia publishes the resolutions for the upcoming bondholder meeting
February 12, 2025
·
6 min read
1 of 77,501
Next
